Health Policy & Advocacy
Resources
Basic InformationMore InformationLatest News
U.S. Gun Violence Rates Jumped 30% During PandemicMandates, Not Recommendations, Work Best to Get Folks Vaccinated: StudyU.S. Has Shared 200 Million Shots With Other CountriesLittle Change Seen in Americans' Use of Mental Health Services During PandemicWomen Doctors Face Higher Levels of Harassment, Frustration: SurveyEPA Plans New Strategy Against PFAS 'Forever Chemicals'State Spending on Poverty Really Pays Off for Kids: StudyState Lotteries Didn't Help Boost Vaccination RatesVaccinated Foreign Travelers Can Enter United States Beginning Nov. 8Despite Pressures of Pandemic, U.S. Nursing School Enrollment ClimbsBiden Administration to Invest $100 Million to Ease Health Worker ShortageFDA Warns Against Using At-Home Dermal Filler 'Pens'Death Threats, Trolling Common for Scientists Who Speak to Media About COVID'Extreme Heat' Days Have Tripled Since 1980s, and More Are ComingAHA News: Are Monolingual Spanish Speakers More at Risk in the Pandemic?Your Free Cancer Screen Shows Trouble: What If You Can't Afford the Follow-Up?Bystanders Can Make the Difference for a Drowning ChildClimate Change is World's Most Pressing Health Problem: WHOAHA News: Another Barrier for Black and Hispanic People: Good Mental Health CareU.S. to Buy $1 Billion Worth of Rapid COVID TestsNearly 200,000 COVID Home Tests Recalled Over False PositivesMedical Mistrust Fuels Vaccine Hesitancy Among HispanicsAmericans Divided on Biden's Vaccine Mandate, Poll FindsAir Pollution Linked to 6 Million Premature Births in 1 YearDelay in Graphic Warning Labels on Cigarettes Cost Lives: StudyAHA News: Women May Be More Willing Than Men to Donate OrgansEPA to Sharply Limit Refrigerant Production in New Climate RuleAHA News: Food Insecurity's Long-Term Health ConsequencesU.S. to Buy 500 Million More COVID Vaccine Doses for Global DonationNIH Spending Nearly $470 Million on Long-Haul COVID StudyCOVAX Cuts Global COVID Vaccine Supply Estimates By a QuarterFDA Bans Sale of Nearly a Million E-Cigarettes; Allows Juul to Remain on MarketMore Affordable Housing, Healthier Hearts?Biden to Strengthen Push for Vaccine Mandates in New COVID PlanU.S. COVID Vaccination Rates Climb in AugustGreener Neighborhoods Bring Healthier Hearts, Study ShowsU.S. to Be Removed From E.U. Safe Travel ListFDA Tells Three Small E-Cigarette Makers to Stop Selling Flavored ProductsFratelli Beretta Antipasto Trays Are the Source of Salmonella Outbreak: CDCHow Your Medicines Make Their Way Into Rivers, Lakes and BaysFamily Behind Oxycontin Denies Any Responsibility for Opioid CrisisCommon Pesticide to Be Banned Over Links to  Problems in ChildrenFar Too Few People of Color in U.S. Pancreatic Cancer TrialsRace-Based Disparities in Americans' Health Haven't Improved: StudyChild Injuries, Deaths Spur Recall of 10 Million Magnet Balls, CubesAmericans Have High Trust in Health Care Providers: PollBreaded, Raw Chicken Recalled in Multi-State Salmonella OutbreakU.S. Military Members Must Get COVID Vaccine by Mid-September6 Tips on Getting Back to Your Regular Doctor's CheckupNursing Home Staff Closest to Patients Are Least Likely to Get COVID Vaccines
Questions and AnswersVideosLinksBook Reviews
Related Topics

Health Insurance
Healthcare

Nearly 200,000 COVID Home Tests Recalled Over False Positives

HealthDay News
by Robert Preidt and Robin Foster
Updated: Oct 6th 2021

new article illustration

WEDNESDAY, Oct. 6, 2021 (HealthDay News) -- Almost 200,000 Ellume COVID-19 home testing kits have been recalled because they may be more likely to give a false positive result.

The problem with the rapid antigen tests was identified in mid-September and caused by variations in the quality of one of the raw materials used in the products, Ellume CEO Dr. Sean Parsons told The New York Times.

The Ellume test kits received emergency use authorization from the U.S. Food and Drug Administration last December, and the Australian company had already shipped about 3.5 million of the test kits to this country.

About 427,000 of those kits were affected by the problem, and about half have already been used, returning about 42,000 positive results, Parsons told the Times.

He said it would be difficult to determine how many of those positive results may have been incorrect, but said the rate could be as high as one quarter.

The issue with the recalled test kits doesn't affect the reliability of negative results, according to the company.

Ellume's test is designed to detect pieces of the virus in the nose. After swabbing the nostrils, the swab is inserted into a dropper of fluid, and the fluid is then added to a Bluetooth-connected analyzer. Results arrive via a smart phone app in 15 minutes.

The company said it has asked retailers to stop selling the recalled kits and has notified consumers about the issue.

Consumers should go to the Ellume website to see if their home test kit is included in the recall and to get instructions on what to do if it is, the company said.

To arrange a replacement, consumers can call Ellume at 1-888-807-1501, 9 a.m. to 5 p.m. ET, Monday through Friday.

People who try to use one of the affected test kits will be notified in the app that the test has been recalled, Parsons explained. "It really won't be possible to use any of those tests now," he added.

He noted that the company had put "extra controls" in place to prevent the same problem from happening again in the future.

"I'm very sorry that this has happened," Parsons told the Times. "We're all about chasing accuracy, and to have these false positives is disappointing."

The recall comes as demand for at-home testing has soared, and consumers have complained that test kits are hard to find, the Times reported.

On Monday, a new at-home antigen test from ACON Laboratories was approved for emergency use by the FDA.

That approval "is expected to double rapid at-home testing capacity in the U.S. over the next several weeks," Dr. Jeffrey Shuren, who directs the FDA's Center for Devices and Radiological Health, said in a statement. "By year's end, the manufacturer plans to produce more than 100 million tests per month, and this number will rise to 200 million per month by February 2022."

"Since March 2020, the FDA has authorized more than 400 COVID-19 tests and sample collection devices, including authorizations for rapid, OTC at-home tests," Shuren added. "The FDA considers at-home COVID-19 diagnostic tests to be a high priority and we have continued to prioritize their review given their public health importance."

More information

Visit the U.S. Centers for Disease Control and Prevention for more on COVID testing.


SOURCE: The New York Times; Oct. 5, 2021 statement, U.S. Food and Drug Administration




Facebook

Amazon Smile

 

Children and Adult services are available now with no wait time.  

Please contact HBH at 860-548-0101, option 2.

 


powered by centersite dot net